NASDAQ:MGNX - MacroGenics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.75 +0.12 (+0.64 %) (As of 05/24/2019 04:00 PM ET)Previous Close$18.63Today's Range$18.44 - $19.0052-Week Range$9.87 - $32.32Volume25,221 shsAverage Volume1.21 million shsMarket Capitalization$915.11 millionP/E RatioN/ADividend YieldN/ABeta2.9 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland. Receive MGNX News and Ratings via Email Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGNX Previous Symbol CUSIPN/A CIK1125345 Webhttp://www.macrogenics.com/ Phone301-251-5172Debt Debt-to-Equity Ratio0.08 Current Ratio6.47 Quick Ratio6.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$60.12 million Price / Sales15.22 Cash FlowN/A Price / Cash FlowN/A Book Value$6.57 per share Price / Book2.85Profitability EPS (Most Recent Fiscal Year)($4.19) Net Income$-171,450,000.00 Net Margins-256.47% Return on Equity-57.65% Return on Assets-44.84%Miscellaneous Employees364 Outstanding Shares48,806,000Market Cap$915.11 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable MacroGenics (NASDAQ:MGNX) Frequently Asked Questions What is MacroGenics' stock symbol? MacroGenics trades on the NASDAQ under the ticker symbol "MGNX." How were MacroGenics' earnings last quarter? MacroGenics Inc (NASDAQ:MGNX) announced its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $0.04. The biopharmaceutical company had revenue of $9.66 million for the quarter, compared to analyst estimates of $11.46 million. MacroGenics had a negative net margin of 256.47% and a negative return on equity of 57.65%. View MacroGenics' Earnings History. When is MacroGenics' next earnings date? MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for MacroGenics. What price target have analysts set for MGNX? 12 analysts have issued 1-year target prices for MacroGenics' shares. Their predictions range from $21.00 to $50.00. On average, they expect MacroGenics' share price to reach $33.38 in the next year. This suggests a possible upside of 76.8% from the stock's current price. View Analyst Price Targets for MacroGenics. What is the consensus analysts' recommendation for MacroGenics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics. What are Wall Street analysts saying about MacroGenics stock? Here are some recent quotes from research analysts about MacroGenics stock: 1. HC Wainwright analysts commented, "Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (18%), flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (5/2/2019) 2. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (3/1/2019) Has MacroGenics been receiving favorable news coverage? Media headlines about MGNX stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. MacroGenics earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. Who are some of MacroGenics' key competitors? Some companies that are related to MacroGenics include ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO), Amneal Pharmaceuticals (AMRX) and Uniqure (QURE). What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Celgene (CELG), Exelixis (EXEL), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Sangamo Therapeutics (SGMO), Karyopharm Therapeutics (KPTI), TherapeuticsMD (TXMD) and Intercept Pharmaceuticals (ICPT). Who are MacroGenics' key executives? MacroGenics' management team includes the folowing people: Dr. Scott Koenig, CEO, Pres & Director (Age 67)Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57) Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include OppenheimerFunds Inc. (9.14%), BlackRock Inc. (6.98%), FMR LLC (3.19%), Wasatch Advisors Inc. (2.65%), Dimensional Fund Advisors LP (2.32%) and Federated Investors Inc. PA (2.26%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Jon Marc Wigginton, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics. Which major investors are selling MacroGenics stock? MGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Voya Investment Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Prosight Management LP, Spark Investment Management LLC, Los Angeles Capital Management & Equity Research Inc. and 361 Capital LLC. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View Insider Buying and Selling for MacroGenics. Which major investors are buying MacroGenics stock? MGNX stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Renaissance Technologies LLC, Rhenman & Partners Asset Management AB, Dimensional Fund Advisors LP, Rubric Capital Management LP, GMT Capital Corp, Wasatch Advisors Inc. and Macquarie Group Ltd.. View Insider Buying and Selling for MacroGenics. How do I buy shares of MacroGenics? Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is MacroGenics' stock price today? One share of MGNX stock can currently be purchased for approximately $18.88. How big of a company is MacroGenics? MacroGenics has a market capitalization of $921.46 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe. What is MacroGenics' official website? The official website for MacroGenics is http://www.macrogenics.com/. How can I contact MacroGenics? MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172. MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 281 (Vote Outperform)Underperform Votes: 295 (Vote Underperform)Total Votes: 576MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Why is momentum important to successful trading? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.